Laplace Interventional, a Minneapolis, MN-based medical device company, raised $22M in Series C funding.
The round was led by a non-disclosed global strategic investor, with participation from Aphelion Capital, Engage Venture Partners, Unorthodox Ventures, JWC Venture and Features Capital.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO and Founder Ramji Iyer, Laplace Interventional develops a device that aims to offer an improvement to the quality of life to patients worldwide diagnosed with Tricuspid Regurgitation (TR). It is providing a prosthetic valve that is delivered through a minimally invasive procedure not requiring an open-heart surgery and thereby reducing future complications in patients.
The company also announced the addition of Ned Scheetz, Founding Managing Partner at Aphelion Capital to its Board of Directors.
FinSMEs
17/03/2025